Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

BACKGROUND/AIMS: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Mol Hepatol
Autori principali: Mölleken, Christian, Ahrens, Maike, Schlosser, Anders, Dietz, Julia, Eisenacher, Martin, Meyer, Helmut E., Schmiegel, Wolff, Holmskov, Uffe, Sarrazin, Christoph, Sorensen, Grith Lykke, Sitek, Barbara, Bracht, Thilo
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Korean Association for the Study of the Liver 2019
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6435967/
https://ncbi.nlm.nih.gov/pubmed/30449076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2018.0029
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi